Eye Damage in Diabetes May Signal Hidden Kidney and Leg Artery Disease

Diabetic retinopathy, the sight-threatening eye disease that affects millions of people with diabetes, may be far more than an isolated ocular complication. A new retrospective cross-sectional study from China suggests that when the small vessels of the retina show damage, the same destructive process is often quietly unfolding elsewhere in the body, particularly in the kidneys and the arteries of the legs. The research, published in BMC Endocrine Disorders, analyzed a carefully balanced dataset of 3,000 patients with type 2 diabetes and found that those with retinopathy carried dramatically higher burdens of diabetic nephropathy, chronic kidney disease, and lower extremity artery disease than those whose retinas remained unaffected.

The study drew on the PHDA Diabetes Complications Data Set maintained by the National Population Health Science Data Center in China. The investigators, Bin Yang of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, and Penglu Yang of the same institution’s First Clinical School, assembled records from patients treated between January 1, 2018, and December 31, 2022. Crucially, they used a predefined 1:1 matching structure: exactly 1,500 patients with diabetic retinopathy and 1,500 without. This balanced design gives the comparison considerable statistical power, because the two groups contribute equally to every estimate and the analysis is not skewed by an overabundance of one type of patient.

The physiological logic behind the findings rests on the shared vulnerability of small blood vessels to chronic hyperglycemia. Diabetic retinopathy develops when persistently elevated blood glucose damages the delicate capillaries that nourish the retina, causing them to leak, become blocked, and eventually grow abnormally. The kidneys contain similarly fine capillary networks in their filtering units, the glomeruli, and the nerves and arteries of the lower limbs are also exposed to the same metabolic assault. Because the retina is the only place in the body where capillaries can be directly visualized noninvasively, ophthalmologists have long speculated that the eye might serve as a window onto the systemic state of the vasculature. The new data lend quantitative weight to that idea.

The numbers are striking. Diabetic nephropathy was present in 60.07 percent of patients with retinopathy but only 24.93 percent of those without, a nearly two-and-a-half-fold difference in raw prevalence. Chronic kidney disease, defined by sustained impairment of kidney filtration function, affected 10.60 percent of the retinopathy group compared with just 1.60 percent of the comparison group, roughly a six-fold gap. Lower extremity artery disease, a manifestation of atherosclerosis in the vessels supplying the legs, was found in 23.73 percent of retinopathy patients versus 7.93 percent of the others. All three differences were highly statistically significant, with p values below 0.001, meaning the probability that they arose by chance alone is vanishingly small.

Beyond categorical diagnoses, the study revealed measurable differences in basic clinical chemistry. Patients with retinopathy had higher glycated hemoglobin, reflecting poorer long-term glucose control, as well as elevated blood pressure, higher serum creatinine, and higher blood urea levels. Most telling was the estimated glomerular filtration rate, or eGFR, a standard index of kidney function calculated from age, sex, and serum creatinine. The retinopathy group averaged 78.95 milliliters per minute per 1.73 square meters of body surface area, compared with 93.05 in the non-retinopathy group. That fifteen-point difference indicates substantially reduced kidney filtration capacity and was statistically significant at the p < 0.001 level.

To move from raw prevalence to adjusted risk, the researchers employed multivariable logistic regression, a statistical technique that estimates the association between an exposure and an outcome while accounting for other variables that could confound the relationship. Here, the models adjusted for age, sex, fasting blood glucose, and HbA1c, the two most important glycemic measures. After adjustment, diabetic retinopathy remained independently associated with lower extremity artery disease with an odds ratio of 3.914, meaning retinopathy patients had nearly four times the odds of leg artery disease. The odds ratio for chronic kidney disease was 2.131, and for diabetic nephropathy it was 1.952. In each case the 95 percent confidence intervals, which ranged from roughly 1.26 to 5.09 across the three outcomes, excluded the null value of 1, indicating statistically robust associations.

One result stands out as counterintuitive: the study found an inverse association between diabetic retinopathy and coronary heart disease, with an odds ratio of 0.507. In other words, patients with retinopathy were about half as likely to have documented coronary heart disease as those without. This is surprising because both conditions are linked to diabetic vascular injury, and much prior literature has posited that retinopathy marks generalized atherosclerotic risk. The authors of the study themselves urge caution in interpreting this finding, noting that the cross-sectional design, the predefined sampling structure of the dataset, and the absence of certain important confounder variables all limit the strength of any causal or directional inference. The inverse coronary signal may reflect selection effects, differences in diagnostic workup between groups, or genuine pathophysiological divergence between microvascular and macrovascular disease, and it will require confirmation in longitudinal cohorts.

The methodological caveats deserve emphasis for readers weighing the clinical implications. A cross-sectional study captures a single moment in time, so it can establish that retinopathy and kidney or leg artery disease co-occur more often than expected, but it cannot prove that one causes the other or even establish the temporal sequence. It is biologically plausible that shared exposure to hyperglycemia, hypertension, and dyslipidemia drives all three conditions in parallel rather than retinopathy somehow triggering renal or peripheral arterial damage. Furthermore, the 1:1 sampling design, while statistically efficient, means the prevalence figures within the dataset do not represent the true prevalence in the general diabetic population, since equal numbers of retinopathy and non-retinopathy patients were deliberately selected. The authors also acknowledge that key confounders such as diabetes duration, smoking status, and medication use were unavailable in the dataset.

Despite these limitations, the study carries a practical message that clinicians and patients can act on today. Diabetic retinopathy is typically diagnosed during routine dilated eye examinations, which many patients with type 2 diabetes already undergo annually. If the presence of retinopathy meaningfully raises the probability of undetected nephropathy or lower extremity artery disease, then an eye clinic finding could serve as an efficient triage signal, prompting intensified screening of kidney function through urine protein measurements and eGFR monitoring, and of leg circulation through ankle-brachial index testing. Early detection of diabetic nephropathy allows interventions such as renin-angiotensin system blockers and newer agents like SGLT2 inhibitors to slow progression, while identifying peripheral artery disease early can prevent the catastrophic outcomes of foot ulcers and amputations.

The broader significance of the work lies in its contribution to a growing body of evidence that diabetic complications should be understood as a systemic syndrome rather than a collection of organ-specific diseases. With more than 140 million people living with diabetes in China and hundreds of millions worldwide, tools that help stratify risk cheaply and early have enormous public health value. The retinal examination, already a cornerstone of diabetes care, may deserve recognition as one of the most informative single data points in the entire clinical assessment. Future longitudinal studies, ideally with repeated retinal imaging and serial kidney and vascular measurements, will be needed to confirm whether the eye truly functions as a predictive sentinel for the rest of the diabetic body, and whether the unexpected inverse coronary finding holds up under scrutiny.

Subject of Research: Associations between diabetic retinopathy and systemic complications in type 2 diabetes

Article Title: Associations between diabetic retinopathy and systemic complications in patients with type 2 diabetes mellitus: a retrospective cross-sectional analysis of the PHDA diabetes complications data set in China

Article References: Yang, B., & Yang, P. (2026). Associations between diabetic retinopathy and systemic complications in patients with type 2 diabetes mellitus: a retrospective cross-sectional analysis of the PHDA diabetes complications data set in China. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02644-w

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02644-w

Keywords: diabetic retinopathy, type 2 diabetes, diabetic nephropathy, chronic kidney disease, lower extremity artery disease, coronary heart disease, eGFR, HbA1c, cross-sectional study, diabetes complications, microvascular disease, China